Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041313 | 0.93 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL18041410 | 0.88 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL21912241 | 0.86 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL18041391 | 0.85 | TLR8 (0.66) | TLR8TLR7 | |
| SCHEMBL21011607 | 0.83 | TLR8 (0.50) | TLR8TLR7 | |
| SCHEMBL25688116 | 0.83 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL25688112 | 0.82 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL19657210 | 0.82 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL17843455 | 0.81 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL18659723 | 0.81 | TLR8 (0.68) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| CN-109153648-B | Benzazepine dicarboxamide compounds having tertiary amide functional group | 豪夫迈·罗氏有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3468963-B1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3468963-B1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-11046671-B2 | Dihydropyrimidinyl benzazepine carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046671-B2 | Dihydropyrimidinyl benzazepine carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020255038-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| EP-3464245-B1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-20200172513-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172513-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10590112-B2 | Dihydropyrimidinyl benzazepine carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10370338-B2 | Benzazepine dicarboxamide compounds with tertiary amide function | HOFFMANN-LA ROCHE INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190135788-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3468963-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| US-20190077763-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | HOFFMANN-LA ROCHE INC. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017216054-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216054-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135788-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | TLR8, TLR1, TLR5 | TLR8 1/4885TLR7 8/4885 |
| US-10590112-B2 | Dihydropyrimidinyl benzazepine carboxamide compounds | TLR8, TLR1, TLR5 | TLR8 1/4885TLR7 8/4885 |
| US-10370338-B2 | Benzazepine dicarboxamide compounds with tertiary amide function | TLR1, TLR5, TLR4 | TLR8 6/4885TLR7 10/4885 |
| US-20190077763-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | TLR1, TLR5, TLR4 | TLR8 6/4885TLR7 10/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | TLR8 158/4885TLR7 60/4885 |
| US-20200172513-A1 | DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS | TLR8, TLR1, TLR5 | TLR8 1/4885TLR7 8/4885 |
| US-11046671-B2 | Dihydropyrimidinyl benzazepine carboxamide compounds | TLR8, TLR1, TLR5 | TLR8 1/4885TLR7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.